Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.

Daghia G, Zabelina T, Zeck G, von Pein UM, Christopeit M, Wolschke C, Ayuk F, Kröger N.

Eur J Haematol. 2019 Oct;103(4):370-378. doi: 10.1111/ejh.13294. Epub 2019 Aug 5.

PMID:
31306511
2.

Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis.

Mannina D, Zabelina T, Wolschke C, Heinzelmann M, Triviai I, Christopeit M, Badbaran A, Bonmann S, von Pein UM, Janson D, Ayuk F, Kröger N.

Br J Haematol. 2019 Aug;186(3):484-489. doi: 10.1111/bjh.15952. Epub 2019 May 15.

PMID:
31090920
3.

Unmodified hydrated С60 fullerene molecules exhibit antioxidant properties, prevent damage to DNA and proteins induced by reactive oxygen species and protect mice against injuries caused by radiation-induced oxidative stress.

Gudkov SV, Guryev EL, Gapeyev AB, Sharapov MG, Bunkin NF, Shkirin AV, Zabelina TS, Glinushkin AP, Sevost'yanov MA, Belosludtsev KN, Chernikov AV, Bruskov VI, Zvyagin AV.

Nanomedicine. 2019 Jan;15(1):37-46. doi: 10.1016/j.nano.2018.09.001. Epub 2018 Sep 19.

PMID:
30240826
4.

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Ayuk F, Beelen DW, Bornhäuser M, Stelljes M, Zabelina T, Finke J, Kobbe G, Wolff D, Wagner EM, Christopeit M, Schmid C, Ottinger H, Groth C, Faul C, Bertz H, Rachlis E, Wolschke C, Schetelig J, Horn PA, Mytilineos J, Guellstorf M, Kelsch R, Fleischhauer K, Kröger N, Bethge W.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2558-2567. doi: 10.1016/j.bbmt.2018.06.026. Epub 2018 Jul 24.

5.

Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation.

Kröger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, Wolschke C.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2152-2156. doi: 10.1016/j.bbmt.2018.05.023. Epub 2018 May 22.

6.

Nuclear DNA as Predictor of Acute Kidney Injury in Patients Undergoing Coronary Artery Bypass Graft: A Pilot Study.

Likhvantsev VV, Landoni G, Grebenchikov OA, Skripkin YV, Zabelina TS, Zinovkina LA, Prikhodko AS, Lomivorotov VV, Zinovkin RA.

J Cardiothorac Vasc Anesth. 2017 Dec;31(6):2080-2085. doi: 10.1053/j.jvca.2017.04.051. Epub 2017 May 1.

PMID:
28967626
7.

Impact of molecular residual disease post allografting in myelofibrosis patients.

Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuk F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N.

Bone Marrow Transplant. 2017 Nov;52(11):1526-1529. doi: 10.1038/bmt.2017.157. Epub 2017 Jul 17.

PMID:
28714945
8.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.

Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz MM, Shahswar R, Ayuk F, Gehlhaar M, Wolschke C, Bollin R, Walter C, Dugas M, Wiehlmann L, Lehmann U, Koenecke C, Chaturvedi A, Alchalby H, Stadler M, Eder M, Christopeit M, Göhring G, Koenigsmann M, Schlegelberger B, Kreipe HH, Ganser A, Stocking C, Fehse B, Thol F, Heuser M.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1095-1101. doi: 10.1016/j.bbmt.2017.03.034. Epub 2017 Apr 4.

9.

Levosimendan for Hemodynamic Support after Cardiac Surgery.

Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, Calabrò MG, Grigoryev EV, Likhvantsev VV, Salgado-Filho MF, Bianchi A, Pasyuga VV, Baiocchi M, Pappalardo F, Monaco F, Boboshko VA, Abubakirov MN, Amantea B, Lembo R, Brazzi L, Verniero L, Bertini P, Scandroglio AM, Bove T, Belletti A, Michienzi MG, Shukevich DL, Zabelina TS, Bellomo R, Zangrillo A; CHEETAH Study Group.

N Engl J Med. 2017 May 25;376(21):2021-2031. doi: 10.1056/NEJMoa1616325. Epub 2017 Mar 21.

10.

PREVENTION OF HEART FAILURE PATIENTS WITH DECREASED EJECTION FRACTION IN NON-CARDIAC SURGERY: LEVOSIMENDAN OR ANESTHETIC CARDIOPROTECTION?.

Likhvantsev VV, Marchenko DN, Grebenshchikov OA, Ubasev YV, Zabelina TS, Timoshin SS, Skripkin YV, Ovezov AM, Lar'kov RN, Philippovskaya ZS, Sungurov VA.

Anesteziol Reanimatol. 2016 Nov;61(6):411-417. English, Russian.

PMID:
29894607
11.

[PERIOPERATIVE MANAGEMENT OF PATIENTS WITH DIABETES MELLITUS.]

Likhvantsev VV, Zabelina TS, Grebenchikov OA, Shapkin MA.

Anesteziol Reanimatol. 2016 Jul;61(4):290-293. Russian.

PMID:
29470899
12.

Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis.

Christopeit M, Badbaran A, Zabelina T, Zeck G, Fehse B, Ayuk F, Wolschke C, Kröger N.

Bone Marrow Transplant. 2016 Oct;51(10):1391-1393. doi: 10.1038/bmt.2016.128. Epub 2016 May 23. No abstract available.

PMID:
27214077
13.

Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis.

Alchalby H, Yunus DR, Zabelina T, Ayuk F, Kröger N.

Bone Marrow Transplant. 2016 Sep;51(9):1223-7. doi: 10.1038/bmt.2016.98. Epub 2016 Apr 18.

PMID:
27088376
14.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.

Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, Cassinat B, Zabelina T, Peffault de Latour R, Ayuk F, Socié G, Kröger N.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1206-1211. doi: 10.1016/j.bbmt.2016.02.019. Epub 2016 Mar 10.

15.

Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.

Christopeit M, Badbaran A, Alawi M, Zabelina T, Zeck G, Wolschke C, Ayuk F, Kröger N.

Eur J Haematol. 2016 Sep;97(3):288-96. doi: 10.1111/ejh.12724. Epub 2016 Feb 15.

PMID:
26680262
16.

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria.

Ayuk F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kröger N.

Ann Hematol. 2015 Oct;94(10):1727-32. doi: 10.1007/s00277-015-2452-6. Epub 2015 Jul 24.

PMID:
26204824
17.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.

Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuk F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübig T, Wolschke C, Bacher U, Kröger N.

Acta Haematol. 2015;134(3):146-54. doi: 10.1159/000380757. Epub 2015 May 5.

PMID:
25968483
18.

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

Kröger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, Vannucchi A, Cazzola M, Morra E, Zabelina T, Maffioli M, Pereira A, Beelen D, Deeg HJ, Passamonti F.

Blood. 2015 May 21;125(21):3347-50; quiz 3364. doi: 10.1182/blood-2014-10-608315. Epub 2015 Mar 17.

19.

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.

Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuk F, von Hünerbein N, Kvasnicka HM, Thiele J, Kreipe HH, Büsche G.

Biol Blood Marrow Transplant. 2014 Jun;20(6):812-5. doi: 10.1016/j.bbmt.2014.02.019. Epub 2014 Mar 1.

20.

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuk F, Kröger N.

Leukemia. 2014 Aug;28(8):1736-8. doi: 10.1038/leu.2014.86. Epub 2014 Feb 26. No abstract available.

PMID:
24569777
21.

Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation.

Ayuk F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kröger N.

Ann Hematol. 2014 May;93(5):855-61. doi: 10.1007/s00277-013-1957-0. Epub 2013 Nov 19.

PMID:
24248672
22.

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.

Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, Beelen D, Cahn JY, Dreger P, Schroyens W, de Witte T, Olavarria E, Kröger N; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2014 Feb;20(2):279-81. doi: 10.1016/j.bbmt.2013.10.027. Epub 2013 Nov 4.

23.

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.

Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, Ayuk F, Wolschke C, Schnittger S, Kohlmann A, Haferlach T, Kröger N.

Eur J Haematol. 2014 Mar;92(3):189-94. doi: 10.1111/ejh.12223. Epub 2013 Nov 21.

PMID:
24164563
24.

Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation.

Wolschke C, Zabelina T, Ayuk F, Alchalby H, Berger J, Klyuchnikov E, Pein UM, Schumacher S, Amtsfeld G, Adjallé R, Wortmann F, Lellek H, Randenborgh A, Zander A, Kröger N.

Bone Marrow Transplant. 2014 Jan;49(1):126-30. doi: 10.1038/bmt.2013.143. Epub 2013 Sep 16.

PMID:
24037022
25.

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML.

Christopeit M, Heiland A, Binder M, Zabelina T, Ayuk F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U.

Bone Marrow Transplant. 2013 Sep;48(9):1257-9. doi: 10.1038/bmt.2013.34. Epub 2013 Apr 8. No abstract available.

PMID:
23562972
26.

Donor choice according to age for allo-SCT for AML in complete remission.

Ayuk F, Zabelina T, Wortmann F, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N.

Bone Marrow Transplant. 2013 Aug;48(8):1028-32. doi: 10.1038/bmt.2013.14. Epub 2013 Feb 18.

PMID:
23419435
27.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.

Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N.

Ann Hematol. 2013 Apr;92(4):487-96. doi: 10.1007/s00277-012-1650-8. Epub 2012 Dec 19.

PMID:
23250623
28.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander AR.

Biol Blood Marrow Transplant. 2013 Mar;19(3):398-404. doi: 10.1016/j.bbmt.2012.10.008. Epub 2012 Oct 16.

29.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS.

Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kröger N, Bacher U.

Bone Marrow Transplant. 2013 Mar;48(3):465-6. doi: 10.1038/bmt.2012.161. Epub 2012 Sep 3. No abstract available.

PMID:
22941378
30.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger KH, Burchert A, Stübig T, Wolschke C, Ayuk F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander AR.

Bone Marrow Transplant. 2013 Mar;48(3):403-7. doi: 10.1038/bmt.2012.142. Epub 2012 Aug 6.

PMID:
22863722
31.

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings.

Kröger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A, Milpied N, Volin L, Mohty M, Leblond V, Blaise D, Finke J, Schaap N, Robin M, de Witte T; MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Leukemia. 2013 Mar;27(3):604-9. doi: 10.1038/leu.2012.210. Epub 2012 Jul 23.

PMID:
22821073
32.

Evaluation of BM cytomorphology after allo-SCT in patients with AML.

Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kröger N, Bacher U.

Bone Marrow Transplant. 2012 Dec;47(12):1538-44. doi: 10.1038/bmt.2012.70. Epub 2012 Apr 30.

PMID:
22543745
33.

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.

Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornhäuser M, Schwerdtfeger R, Bethge W, Kvasnicka HM, Büsche G, Ayuk F, Bacher U, Zander AR, Kröger N.

Br J Haematol. 2012 Apr;157(1):75-85. doi: 10.1111/j.1365-2141.2011.09009.x. Epub 2012 Jan 27.

PMID:
22280409
34.

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.

Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hilde-brandt Y, Atanackovic D, Alchalby H, Ayuk F, Zander AR, Bacher U, Eiermann T.

Leukemia. 2011 Oct;25(10):1657-61. doi: 10.1038/leu.2011.138. Epub 2011 Jun 7. No abstract available.

PMID:
21647155
35.

Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.

Alchalby H, Lioznov M, Fritzsche-Friedland U, Badbaran A, Zabelina T, Bacher U, Stübig T, Ayuk FA, Zander AR, Kröger N.

Bone Marrow Transplant. 2012 Jan;47(1):143-5. doi: 10.1038/bmt.2011.17. Epub 2011 Feb 28. No abstract available.

PMID:
21358677
36.

Second allogeneic stem cell transplantation in a patient with hypoplastic myelodysplastic syndrome following a primary diagnosis of aplastic anaemia.

Ocheni S, Oyekunle A, Kröger N, Ayuk F, Klyuchnikov E, Arps S, Held K, Zabelina T, Adjallé R, Wolschke C, Zander AR, Bacher U.

Acta Haematol. 2011;125(3):175-8. doi: 10.1159/000322609. Epub 2010 Dec 30. No abstract available.

PMID:
21196720
37.

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.

Klyuchnikov E, Bacher U, Kröger N, Kazantsev I, Zabelina T, Ayuk F, Zander AR.

Adv Hematol. 2011;2011:974658. doi: 10.1155/2011/974658. Epub 2010 Oct 26.

38.

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.

Kröger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T; MDS Subcommittee of the Chronic Leukemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EBMT).

Haematologica. 2011 Feb;96(2):291-7. doi: 10.3324/haematol.2010.031229. Epub 2010 Oct 22.

39.

Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents.

Schmidt-Hieber M, Schwender J, Heinz WJ, Zabelina T, Kühl JS, Mousset S, Schüttrumpf S, Junghanss C, Silling G, Basara N, Neuburger S, Thiel E, Blau IW.

Haematologica. 2011 Jan;96(1):142-9. doi: 10.3324/haematol.2010.029876. Epub 2010 Sep 17.

40.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.

Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander AR, Bacher U.

Exp Hematol. 2010 Dec;38(12):1261-71. doi: 10.1016/j.exphem.2010.08.006. Epub 2010 Sep 17.

PMID:
20851159
41.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.

Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuk F, Zander AR, Fehse B, Bacher U.

Leuk Lymphoma. 2010 Oct;51(10):1837-43. doi: 10.3109/10428194.2010.508822.

PMID:
20849383
42.

Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny.

Cavattoni I, Ayuk F, Zander AR, Zabelina T, Bacher A, Cayroglu E, Knospe V, Illies T, Aepfelbacher M, Richard G, Kröger N, Bacher U.

Leuk Lymphoma. 2010 Aug;51(8):1530-5. doi: 10.3109/10428194.2010.494260.

PMID:
20578813
43.

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.

Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornhäuser M, Thiede C, Baurmann H, Bethge W, Hildebrandt Y, Bacher U, Fehse B, Zander AR, Kröger N.

Blood. 2010 Nov 4;116(18):3572-81. doi: 10.1182/blood-2009-12-260588. Epub 2010 May 20.

PMID:
20489052
44.

Second allogeneic stem cell transplantation in myeloid malignancies.

Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander AR, Bacher U.

Acta Haematol. 2009;122(4):185-92. doi: 10.1159/000253025. Epub 2009 Oct 29.

PMID:
19887774
45.

Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation.

Cavattoni I, Zabelina T, Ayuk F, Wolschke C, Bacher U, Zander A, Kröger N.

Leuk Lymphoma. 2010 Jan;51(1):146-8. doi: 10.3109/10428190903275594. No abstract available.

PMID:
19860607
46.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM.

Blood. 2009 Dec 17;114(26):5264-70. doi: 10.1182/blood-2009-07-234880. Epub 2009 Oct 7.

PMID:
19812383
47.

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.

Klyuchnikov E, Schafhausen P, Kröger N, Brummendorf TH, Osanmaz O, Asenova S, Zabelina T, Ocheni S, Ayuk F, Zander AR, Bacher U.

Acta Haematol. 2009;122(1):6-10. doi: 10.1159/000228587. Epub 2009 Jul 15. No abstract available.

PMID:
19602874
48.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.

Kröger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y, Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander A.

Exp Hematol. 2009 Jul;37(7):791-8. doi: 10.1016/j.exphem.2009.03.008. Epub 2009 May 31.

PMID:
19487069
49.

Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors.

Neth OW, Bacher U, Das P, Zabelina T, Kabisch H, Kroeger N, Ayuk F, Lioznov M, Waschke O, Fehse B, Thiébaut R, Haston RM, Klein N, Zander AR.

Bone Marrow Transplant. 2010 Jan;45(1):13-9. doi: 10.1038/bmt.2009.90. Epub 2009 May 11.

50.

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.

Ocheni S, Iwanski GB, Schafhausen P, Zander AR, Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brümmendorf TH, Kröger N, Bacher U.

Leuk Lymphoma. 2009 Apr;50(4):551-8. doi: 10.1080/10428190902755513.

PMID:
19373652

Supplemental Content

Loading ...
Support Center